Emerald Medical Applications Corp. (OTCQB: MRLA), f/k/a Zaxis International Inc., a Delaware corporation (the “Registrant”), effective July 14, 2015, completed a Share Exchange Agreement with Emerald Medical Applications Ltd, an Israeli company, which became the Registrant’s wholly-owned subsidiary. Emerald is engaged in the business of commercially exploiting its proprietary “DermaCompare” technology for the early detection of skin cancer using unique, cloud-based software.
Emerald has entered into several distgribution agreements and has already commenced marketing activity of its DermaCompare Technology directly to medical professionals and facilities in Italy, Netherlands, Sweden, Israel, Australia and New Zealand. Emerald is continuing to negotiate for additional distribution agreements throughout Europe, North America, Asia and elsewhere.
The DermaCompare Technology is designed to revolutionize the diagnosis and early detection of skin cancer thereby significantly reducing mortality. The DermaCompare platfor quickly analyzies the patient’s skin condition data which is transmitted to the physician in real-time, thereby pdermitting the physician to complete evaluation and diagnosis of the presence or absence of skin cancer. Emerald is continuing development of next generation enhancements of its technology.
The major target markets for DermaCompare include HMOs, insurance companies, medical centers, dermatologist groups and medical research institutes. In furtherance of its ongoing business plan, Emerald has established relationships with several public and private medical centers and clinics as well as with a leading University Medical Center in Israel.
OTC Disclosure & News Service: